Illustrating this, BRAF V600E and NRAS Q61R appeared to be selected more strongly than KRAS G12D in melanoma and thyroid cancer, but more weakly than this mutation in pancreatic cancer. This evidence concerns the gene NRAS and thyroid cancer.